Moderna, Inc. (NASDAQ:MRNA) Receives $79.50 Average Target Price from Analysts

Moderna, Inc. (NASDAQ:MRNA) has been given a consensus recommendation of “Hold” by the twenty-two research firms that are presently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $78.83.

Several brokerages have commented on MRNA. Wolfe Research began coverage on shares of Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Barclays cut their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Argus cut Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Jefferies Financial Group decreased their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently made changes to their positions in MRNA. Larson Financial Group LLC lifted its holdings in shares of Moderna by 1,753.1% during the 2nd quarter. Larson Financial Group LLC now owns 593 shares of the company’s stock worth $70,000 after acquiring an additional 561 shares during the period. TD Asset Management Inc grew its stake in shares of Moderna by 13.8% during the 2nd quarter. TD Asset Management Inc now owns 162,137 shares of the company’s stock valued at $19,254,000 after buying an additional 19,599 shares during the period. Private Advisor Group LLC grew its stake in shares of Moderna by 112.1% during the 2nd quarter. Private Advisor Group LLC now owns 30,733 shares of the company’s stock valued at $3,650,000 after buying an additional 16,243 shares during the period. Lake Street Advisors Group LLC raised its position in shares of Moderna by 6.8% in the 2nd quarter. Lake Street Advisors Group LLC now owns 3,991 shares of the company’s stock worth $474,000 after buying an additional 253 shares during the period. Finally, Asset Dedication LLC raised its position in shares of Moderna by 41.8% in the 2nd quarter. Asset Dedication LLC now owns 1,018 shares of the company’s stock worth $121,000 after buying an additional 300 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 9.2 %

MRNA stock opened at $43.17 on Tuesday. Moderna has a one year low of $35.80 and a one year high of $170.47. The firm has a market cap of $16.61 billion, a PE ratio of -7.42 and a beta of 1.60. The firm’s 50 day moving average price is $42.99 and its 200-day moving average price is $70.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities research analysts anticipate that Moderna will post -9.3 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.